Reverse DCF
What growth does the market imply for JBCHEPHARM?
Working backwards from the current price to find the FCF growth assumption baked in.
very aggressive
21.7% implied annual FCF growth
The market is pricing in exceptional growth that only a handful of companies sustain for a decade. For context, this company has historically grown at 7.3%. High execution risk.
Current Price
₹2,258
Historical Growth
7.3%
FCF Yield
1.71%
Price / FCF
58.4x
Plain English
To justify today's price of ₹2257.70, JBCHEPHARM.NS needs to grow its free cash flow at 21.7% per year for the next 10 years. That is 14.4% faster than its historical growth rate of 7.3%. At its historical growth rate, the stock cannot justify its current price within a 20-year horizon. The market is pricing in a step-change in performance.
Adjust Assumptions
Growth Scenarios
What the stock is worth at different growth assumptions
| Scenario | FCF Growth | Implied IV | MoS vs Price |
|---|---|---|---|
| Historical | 7.3% | ₹749 | -66.8% |
| GDP rate | 10.0% | ₹922 | -59.2% |
| Half implied | 10.8% | ₹984 | -56.4% |
| Implied | 21.7% | ₹2,258 | +0.0% |
At Historical Growth Rate
DCF horizon: 10 years. At 7.3% growth, the model values JBCHEPHARM at ₹749, below today's ₹2,258.
See full DCF analysis
Bear/base/bull scenarios, sensitivity heatmap, reverse DCF, and more.
Run Full Analysis →This is an analytical tool, not investment advice. Implied growth is a mathematical inversion of the DCF model and depends on WACC and terminal growth assumptions. YieldIQ is not registered with SEBI as an investment adviser.